Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2005 2
2006 8
2007 15
2008 20
2009 28
2010 28
2011 46
2012 33
2013 35
2014 42
2015 50
2016 41
2017 42
2018 49
2019 50
2020 30
Text availability
Article attribute
Article type
Publication date

Search Results

450 results
Results by year
Filters applied: . Clear all
Page 1
Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease.
Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Hohenberger M, et al. J Dermatolog Treat. 2018 Feb;29(1):13-18. doi: 10.1080/09546634.2017.1329511. Epub 2017 May 31. J Dermatolog Treat. 2018. PMID: 28521565 Review.
INTRODUCTION: Interleukin 17 (IL-17) antagonism provides a highly effective approach for treating psoriasis. Exacerbations of inflammatory bowel disease have been reported in anti-IL-17 psoriasis trials. ...The placebo groups fared …
INTRODUCTION: Interleukin 17 (IL-17) antagonism provides a highly effective approach for treating psoriasis. Exa …
Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases.
Bunte K, Beikler T. Bunte K, et al. Int J Mol Sci. 2019 Jul 10;20(14):3394. doi: 10.3390/ijms20143394. Int J Mol Sci. 2019. PMID: 31295952 Free PMC article. Review.
In addition, Th17 cells, their key cytokine IL-17, and IL-23 seem to play pivotal roles. This review aims to provide an overview of the current knowledge about the differentiation of Th17 cells and the role of the IL-17/IL-23 axis in the …
In addition, Th17 cells, their key cytokine IL-17, and IL-23 seem to play pivotal roles. This review aims to provide an …
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.
Moschen AR, Tilg H, Raine T. Moschen AR, et al. Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):185-196. doi: 10.1038/s41575-018-0084-8. Nat Rev Gastroenterol Hepatol. 2019. PMID: 30478416 Review.
Ustekinumab, a therapeutic antibody targeting both cytokines is now widely licensed for the treatment of Crohn's disease, including in Europe, the USA, Canada and Japan, whilst agents targeting IL-23 specifically are in late-phase clinical trials. We review t …
Ustekinumab, a therapeutic antibody targeting both cytokines is now widely licensed for the treatment of Crohn's disease, incl …
Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies.
Ruiz de Morales JMG, Puig L, Daudén E, Cañete JD, Pablos JL, Martín AO, Juanatey CG, Adán A, Montalbán X, Borruel N, Ortí G, Holgado-Martín E, García-Vidal C, Vizcaya-Morales C, Martín-Vázquez V, González-Gay MÁ. Ruiz de Morales JMG, et al. Autoimmun Rev. 2020 Jan;19(1):102429. doi: 10.1016/j.autrev.2019.102429. Epub 2019 Nov 15. Autoimmun Rev. 2020. PMID: 31734402 Free article. Review.
Interleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of intensive research because of its crucial role in the pathogenesis of different diseases across many medical specialties. ...A comprehensive review of the literature and an
Interleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of intensive research because of it
Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions.
Frieder J, Kivelevitch D, Haugh I, Watson I, Menter A. Frieder J, et al. Clin Pharmacol Ther. 2018 Jan;103(1):88-101. doi: 10.1002/cpt.893. Epub 2017 Oct 19. Clin Pharmacol Ther. 2018. PMID: 28960267 Review.
Advancements in the immunopathogenesis of psoriasis have identified interleukin (IL)-23 and IL-17 as fundamental contributors in the immune pathways of the disease. ...Here we review the IL-23/IL-17 immune pathways and discu …
Advancements in the immunopathogenesis of psoriasis have identified interleukin (IL)-23 and IL-17 as fundamental …
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?
Baker KF, Isaacs JD. Baker KF, et al. Ann Rheum Dis. 2018 Feb;77(2):175-187. doi: 10.1136/annrheumdis-2017-211555. Epub 2017 Aug 1. Ann Rheum Dis. 2018. PMID: 28765121 Review.
The past three decades have witnessed remarkable advances in our ability to target specific elements of the immune and inflammatory response, fuelled by advances in both biotechnology and disease knowledge. ...We review novel biologic agents targeting the T-helper 17
The past three decades have witnessed remarkable advances in our ability to target specific elements of the immune and inflammatory response …
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB; MEASURE 1 Study Group; MEASURE 2 Study Group. Baeten D, et al. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066. N Engl J Med. 2015. PMID: 26699169 Free article. Clinical Trial.
BACKGROUND: Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. ...During the entire treatment period, pooled exposure-adjusted incidence rates of grade 3 or 4 neutropenia, can …
BACKGROUND: Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing spon …
Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases.
Fragoulis GE, Siebert S, McInnes IB. Fragoulis GE, et al. Annu Rev Med. 2016;67:337-53. doi: 10.1146/annurev-med-051914-021944. Epub 2015 Nov 4. Annu Rev Med. 2016. PMID: 26565676 Review.
The discovery of the biological functions of the interleukin-23/-17 axis led to the identification of IL-23 and IL-17 as important participants in the pathogenesis of several immune-mediated diseases. ...Anti-IL-17 and anti-IL
The discovery of the biological functions of the interleukin-23/-17 axis led to the identification of IL-23 and IL
Crohn's Disease and Ulcerative Colitis Show Unique Cytokine Profiles.
Nemeth ZH, Bogdanovski DA, Barratt-Stopper P, Paglinco SR, Antonioli L, Rolandelli RH. Nemeth ZH, et al. Cureus. 2017 Apr 19;9(4):e1177. doi: 10.7759/cureus.1177. Cureus. 2017. PMID: 28533995 Free PMC article.
INTRODUCTION: Networks of cytokines have been implicated in both forms of inflammatory bowel disease (IBD): Crohn's disease (CD) and ulcerative colitis (UC). ...RESULTS: In both CD and UC, interleukin (IL)-12 (p40), IL-18, IL-21 an …
INTRODUCTION: Networks of cytokines have been implicated in both forms of inflammatory bowel disease (IBD): Crohn's disease
Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents.
Kaushik SB, Lebwohl MG. Kaushik SB, et al. J Am Acad Dermatol. 2019 Jan;80(1):27-40. doi: 10.1016/j.jaad.2018.06.057. Epub 2018 Jul 11. J Am Acad Dermatol. 2019. PMID: 30017705 Review.
Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities, such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular diseases. ...Treatment regimens for psoriasis patients should be tailored to me …
Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities, such as psoriatic arthritis, Crohn
450 results
Jump to page
Feedback